Clinical Commissioning Policy Statement: Nusinersen for genetically confirmed Spinal Muscular Atrophy (SMA) type 1 for eligible patients under the Expanded Access Programme (EAP)

Document first published:
Page updated:
Topic:
,
Publication type:

This clinical commissioning policy statement is an interim commissioning position pending the formation of a clinical policy.